HEPATITIS C TREATMENT CONTINUATION RATES IN TREATMENT-NAIVE GENOTYPE 1 PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM

被引：0

作者：

Mussolino, F. ^{[1
]}

Vaz, P. ^{[1
]}

Morais, A. D. ^{[2
]}

Pereira, M. L. ^{[2
]}

机构：

[1] NEW BD Business Developers, Sao Paulo, Brazil

[2] Janssen Cilag Farmaceut, Sao Paulo, Brazil

来源：

VALUE IN HEALTH | 2011年 / 14卷 / 07期

关键词：

D O I：

10.1016/j.jval.2011.08.273

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A281 / A281

页数：1

共 50 条

[31] ADDITIONAL BOCEPREVIR INCREASES SUSTAINED VIROLOGICAL RESPONSE (SVR) RATES IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION
Desai, Mitesh
SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 (05) : 449 - 449
[32] DIFFERENCE IN HEALTH CARE UTILIZATION IN EUROPE BETWEEN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C AND PATIENTS WHO FAILED PRIOR THERAPY
Zhang, H.
Narayanan, S.
VALUE IN HEALTH, 2008, 11 (06) : A442 - A442
[33] C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE
Roth, D.
Nelson, D.
Bruchfeld, A.
Liapakis, A.
Silva, M.
Monsour, H., Jr.
Martin, P.
Pol, S.
Londono, M. -C.
Hassanein, T.
Zamor, P.
Zuckerman, E.
Zhao, Y.
Wan, S.
Jackson, B.
Robertson, M.
Wahl, J.
Barr, E.
Greaves, W.
JOURNAL OF HEPATOLOGY, 2015, 62 : S263 - S264
[34] Shortened treatment duration in treatment-naive genotype 6 chronic hepatitis C patients with rapid virological response: A randomized controlled trial
Cai Qing-Xian
Zhao Zhixin
Lin, Chaoshuang
Min, Xu
Min, Wei
Huang Mingshou
HEPATOLOGY, 2013, 58 : 1098A - 1098A
[35] C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE
Bruchfeld, Annette
Roth, David
Nelson, David
Liapakis, AnneMarie
Silva, Marcelo
Monsour, Howard
Martin, Paul
Pol, Stanislas
Londono, Maria-Carlota
Hassanein, Tarek
Zamor, Philippe
Zuckerman, Eli
Zhao, Yue
Robertson, Michael
Wahl, Janice
Barr, Eliav
Greaves, Andwayne
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
[36] Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life'
Ridruejo, Ezequiel
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (02) : 195 - 195
[37] Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population
Chahal, Harinder S.
Marseille, Elliot A.
Tice, Jeffrey A.
Pearson, Steve D.
Ollendorf, Daniel A.
Fox, Rena K.
Kahn, James G.
JAMA INTERNAL MEDICINE, 2016, 176 (01) : 65 - 73
[38] Viral kinetics and pharmacodynamics of albinterferon alfa-2b in interferon treatment-NaiVe patients with genotype 1, chronic hepatitis C
Neumann, Avidan U.
Rozenberg, Lynn
Bain, Vincent G.
McHutchison, John G.
Pulkstenis, Erik
Subramanian, Mani
GASTROENTEROLOGY, 2008, 134 (04) : A788 - A788
[39] Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection
Lisboa-Neto, Gaspar
Noble, Caroline F.
Rebello Pinho, Joao R.
Malta, Fernanda M.
Gomes-Gouvea, Michele S.
Alvarado-Mora, Monica V.
da Silva, Mariliza H.
Leite, Andrea G. B.
Piccoli, Leonora Z.
Rodrigues, Flaviane K.
Carrilho, Flair J.
Mendes-Correa, Maria C.
ANTIVIRAL THERAPY, 2015, 20 (03) : 281 - 287
[40] Efficacy and safety of grazoprevir plus ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection
Gane, E.
Ben Ari, Z.
Mollison, L.
Zuckerman, E.
Bruck, R.
Baruch, Y.
Howe, A. Y. M.
Wahl, J.
Bhanja, S.
Hwang, P.
Zhao, Y.
Robertson, M. N.
JOURNAL OF VIRAL HEPATITIS, 2016, 23 (10) : 789 - 797

← 1 2 3 4 5 →